Alerts will be sent to your verified email
Verify Email
ASTRAZEN
|
Astrazeneca Pharma I
|
Alembic Pharma
|
Eris Lifesciences
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Domestic Sales Growth - YoY
|
18.6 % | n/a | 10.7 % |
|
R&D as a % of Total Sales
|
0.0 | 7.0 % | 0.0 |
|
Financials
|
|||
|
5 yr Average ROE
|
18.37 % | 15.79 % | 19.85 % |
|
5yr average Equity Multiplier
|
1.94 | 1.48 | 1.5 |
|
5yr Average Asset Turnover Ratio
|
0.94 | 0.83 | 0.58 |
|
5yr Avg Net Profit Margin
|
10.03 % | 13.0 % | 25.85 % |
|
Price to Book
|
27.61 | 3.54 | 6.05 |
|
P/E
|
228.97 | 28.61 | 50.9 |
|
5yr Avg Cash Conversion Cycle
|
-36.14 Days | 1.45 Days | -99.43 Days |
|
Inventory Days
|
64.11 Days | 94.67 Days | 26.22 Days |
|
Days Receivable
|
36.53 Days | 60.69 Days | 61.69 Days |
|
Days Payable
|
208.62 Days | 176.63 Days | 164.23 Days |
|
5yr Average Interest Coverage Ratio
|
140.96 | 36.16 | 94.87 |
|
5yr Avg ROCE
|
23.99 % | 17.34 % | 21.14 % |
|
5yr Avg Operating Profit Margin
|
14.51 % | 19.56 % | 34.25 % |
|
5 yr average Debt to Equity
|
0.0 | 0.2 | 0.29 |
|
5yr CAGR Net Profit
|
17.47 % | -5.77 % | 5.74 % |
|
5yr Average Return on Assets
|
9.52 % | 10.48 % | 15.49 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
75.0 % | 69.61 % | 54.86 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 18.51 % |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.13 % | 2.2 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
4.07 % | 4.0 % | 6.53 % |
|
Astrazeneca Pharma I
|
Alembic Pharma
|
Eris Lifesciences
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
|
Dosage Form Break-Up
|
Dosage Form Break-Up
|
-
|
-
|